Does Rallies track congressional trades in PFE?

Yes. Rallies tracks politician and congressional stock disclosures for PFE, including reported purchases, sales, dates, owners, and trade amounts when available.

Is PFE research on Rallies investment advice?

No. Rallies provides research, data, and educational context for PFE. It does not provide personalized investment advice.

PFE (Pfizer) Stock Analysis - Politician Trades

Pfizer (PFE) is a publicly traded Healthcare sector company. As of May 20, 2026, PFE trades at $25.81 with a market cap of $144.37B and a P/E ratio of 19.70. PFE moved +0.47% today. Year to date, PFE is +1.91%; over the trailing twelve months it is +11.57%. Its 52-week range spans $20.92 to $30.43. Analyst consensus is neutral with an average price target of $29.17. Rallies surfaces PFE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Which politicians traded PFE stock?

Recent politician trading activity in PFE includes disclosures from Gilbert Cisneros, Susan M. Collins, James French Hill, Ron Wyden, and Josh Gottheimer. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.

PFE Key Metrics

Key financial metrics for PFE
Metric	Value
Price	$25.81
Market Cap	$144.37B
P/E Ratio	19.70
EPS	$1.31
Dividend Yield	0.43%
52-Week High	$30.43
52-Week Low	$20.92
Volume	29.35M
Avg Volume	0
Revenue (TTM)	$63.31B
Net Income	$7.53B
Gross Margin	73.51%

Congressional Trades in PFE

Gilbert Cisneros purchase PFE on Feb 10, 2026 (amount: $15.00K).
Susan M. Collins purchase PFE on Feb 3, 2026 (amount: $50.00K) for Spouse.
James French Hill sale PFE on Dec 31, 2025 (amount: $250.00K).
Ron Wyden sale PFE on Jun 3, 2025 (amount: $15.00K) for Spouse.
Josh Gottheimer sale PFE on Jun 3, 2025 (amount: $15.00K) for Joint.

Latest PFE News

Pfizer Advances 25-Valent Vaccine with up to 15x Stronger Immune Response — May 20, 2026
Pfizer gains EU approval for Hympavzi, Phase III shows 93% bleed reduction — May 15, 2026
Pfizer Q1 Revenue Rises 5.7% to $14.5B, Acquisitions Drive $3.1B Growth — May 14, 2026
Pfizer Stock Drops 2.6% Despite Q1 Earnings Beat as Markets Rally — May 8, 2026
Pfizer CEO Backs CDC Nominee Erica Schwartz, Signaling Vaccine Policy Stability — May 6, 2026

PFE Analyst Consensus

22 analysts cover PFE: 0 strong buy, 8 buy, 11 hold, 3 sell, 0 strong sell. Consensus rating is neutral. Average price target: $29.17.

Common questions about PFE

Which politicians traded PFE stock?: Recent politician trading activity in PFE includes disclosures from Gilbert Cisneros, Susan M. Collins, James French Hill, Ron Wyden, and Josh Gottheimer. Rallies tracks purchase and sale disclosures, transaction dates, owners, reported amounts, and post-trade performance context.
Does Rallies track congressional trades in PFE?: Yes. Rallies tracks politician and congressional stock disclosures for PFE, including reported purchases, sales, dates, owners, and trade amounts when available.
Is PFE research on Rallies investment advice?: No. Rallies provides research, data, and educational context for PFE. It does not provide personalized investment advice.